- Home
- TLSI vs VTYX Comparison
TLSI vs VTYX Comparison
Compare TLSI & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- VTYX
- Stock Information
- Founded
- TLSI 2010
- VTYX 2018
- Country
- TLSI United States
- VTYX United States
- Employees
- TLSI N/A
- VTYX N/A
- Industry
- TLSI Medical Specialities
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- TLSI Health Care
- VTYX Health Care
- Exchange
- TLSI Nasdaq
- VTYX Nasdaq
- Market Cap
- TLSI 160.4M
- VTYX 154.9M
- IPO Year
- TLSI N/A
- VTYX 2021
- Fundamental
- Price
- TLSI $5.19
- VTYX $1.17
- Analyst Decision
- TLSI Strong Buy
- VTYX Buy
- Analyst Count
- TLSI 6
- VTYX 4
- Target Price
- TLSI $11.75
- VTYX $11.33
- AVG Volume (30 Days)
- TLSI 34.3K
- VTYX 965.2K
- Earning Date
- TLSI 05-14-2025
- VTYX 05-16-2025
- Dividend Yield
- TLSI N/A
- VTYX N/A
- EPS Growth
- TLSI N/A
- VTYX N/A
- EPS
- TLSI N/A
- VTYX N/A
- Revenue
- TLSI $29,431,000.00
- VTYX N/A
- Revenue This Year
- TLSI $56.00
- VTYX N/A
- Revenue Next Year
- TLSI $52.17
- VTYX N/A
- P/E Ratio
- TLSI N/A
- VTYX N/A
- Revenue Growth
- TLSI 58.99
- VTYX N/A
- 52 Week Low
- TLSI $3.50
- VTYX $0.78
- 52 Week High
- TLSI $10.24
- VTYX $5.66
- Technical
- Relative Strength Index (RSI)
- TLSI 40.35
- VTYX 46.01
- Support Level
- TLSI $4.66
- VTYX $1.05
- Resistance Level
- TLSI $5.35
- VTYX $1.48
- Average True Range (ATR)
- TLSI 0.37
- VTYX 0.11
- MACD
- TLSI -0.05
- VTYX 0.01
- Stochastic Oscillator
- TLSI 43.44
- VTYX 27.91
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.